DestinationRx launches Web site to assist customers in managing prescriptions
LOS ANGELES A company that supplies pricing, safety and efficacy information on drugs to consumers announced Monday that it had launched an online service to help consumers manage their medications.
DestinationRx launched a Web site, www.destinationrx.com, designed to help consumers compare and enroll in Medicare Part D, compare the efficacy and side effects of more than 800 prescription drugs and access their prescription drug information electronically.
“DestinationRx is like having a pharmacist who makes house calls,” DestinationRx president and chief executive officer Michael Cho said. “Now, consumers will be able to get all the information they need to make decisions about the medications they need for themselves and their families.”
Rite Aid reports cash dividend payout for preferred stock
CAMP HILL, Pa. Rite Aid on Monday declared a cash dividend of $0.4049 per share on its 5.5 percent Series I Mandatory Convertible Preferred Stock for the period commencing on Aug. 1, 2008 through Nov. 16, 2008.
The dividend is payable on Nov. 17, 2008 to shareholders of record as of Oct. 15, 2008, the company stated.
Deciphera, Lilly partner to test compounds in treatment of cancer
INDIANAPOLIS Eli Lilly and Deciphera Pharmaceuticals said Friday they would collaborate to investigate a group of Deciphera compounds as a potential cancer treatment.
The companies said they would investigate Deciphera’s preclinical B-Raf kinase inhibitors as cancer treatments, combining Deciphera’s drug-discovery resources and Lilly’s drug discovery, development and commercialization resources.
“This collaboration is further evidence of Lilly’s ongoing commitment to oncology research,” Lilly vice president for discovery research and clinical investigation Dr. William Chin said. “We look forward to working with Deciphera to leverage their B-Raf kinase inhibitor program, with the ultimate goal of developing promising drug candidates for cancer patients.”
As part of the deal, Lilly will obtain exclusive worldwide rights to any products developed as part of the collaboration, while Deciphera will receive an upfront payment and research funding, as well as up to $130 million in development, regulatory and sales milestone payments.